Chemetics proof is in the deal making
Nuevolution’s proprietary Chemetics DNA-encoded screening platform technology enables fast and accurate small molecule drug discovery. The technology has received powerful external validation, including two recent collaborations (Amgen and Almirall) that could generate significant value in the coming years. In addition, we expect Nuevolution to progress at least one internally generated asset into clinical development in the near future. We value the company's recent deals with Amgen and Almirall, plus its cash position alone, at SEK901m ($102m); our valuation does not include the technology, other pipeline assets and future deal opportunities.Nuevolution AB (publ). Nuevolution AB is a Sweden-based biopharmaceutical company working to develop future medicine for the treatment of cancer and inflammatory diseases. The Company's business is conducted through its wholly owned subsidiary, Nuevolution A/S.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.